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Poster Session-I 41misfold, form fibrils and deposit in vital organs causing malfunction
and death. HDM/SCT can produce hematologic remissions and
prolong survival. HDM/SCT was developed for the treatment of
AL at BostonUniversityMedical Center in 1994. In 1996, treatment
was moved to the outpatient setting. The program has been FACT-
accredited since 2000. To date, we have performed 496 SCTs. 95%
of patients are offered outpatient treatment. While patients with se-
vere cardiac involvement are not candidates forHDM/SCT, patients
with less severe cardiac disease can undergo HDM/SCT, with inpa-
tient cardiac monitoring. The CP begins with an extensive multidis-
ciplinary team evaluation involving members from hematology,
nephrology, cardiology, pulmonology, neurology, psychiatry, nurs-
ing, nutrition, clinical research and the amyloid program. The eval-
uation involves 3 days of visits which assess organ involvement,
performance status, support network including their ability to phys-
ically and emotionally adhere to an outpatient treatment program as
well as to post-transplant follow-up, and candidacy for a research
protocol. Weekly meetings are held to discuss evaluation results
and determine eligibility before a patient can be scheduled. Once
treatment begins, daily rounds, including toxicity evaluations, phys-
ical exams, medication review and reinforcement of the treatment
plan are conducted. Oral and written instructions are provided re-
garding expected toxicities, symptom management and emergency
contacts. Prophylactic treatment with antiemetic, antibacterial, anti-
viral, antifungal and growth factors are used. Themost common rea-
son for hospital admission is febrile neutropenia. Severe nausea,
vomiting, diarrhea, dehydration may also necessitate hospitalization.
CPs and SOPs were developed early on in the program and are
adhered to with a mechanism to document any deviations. CPs are
reviewed annually for revisions based on current peer-reviewed liter-
ature and program experience. Educational short courses are held
regularly for staff to insure adherence to CPs and SOPs. In summary,
outpatient HDM/SCT is a feasible treatment option for patients
with AL amyloidosis, provided treatment is conducted in an experi-
enced center.102
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY
REVERSE RENAL FAILURE IN PATIENTS WITH MULTIPLE MYELOMA
Kazmi, S.M.A., Parikh, G.C., Lahoti, A., Mendoza, F., Hosing, C.,
Popat, U., Alousi, A.M., Weber, D.M., Wang, M., Champlin, R.E.,
Giralt, S.A., Qazilbash, M.H. UT - MDAnderson Cancer Center, Hous-
ton, TX
Background: Approximately 20% of patients with multiple my-
eloma (MM) have renal failure at diagnosis, and about 5% are di-
alysis-dependent. These patients may potentially benefit from
high-dose chemotherapy and autologous hematopoietic stem cell
transplantation (auto SCT). However, many of these patients are
considered ineligible for auto SCT due to concerns about in-
creased treatment-related toxicity. We evaluated the outcome of
46 patient with MM and renal failure, defined as serum creatinine
.2 mg/dl sustained for .1 month, who received auto SCT at our
institution.
Methods: Forty-six patients with a median age of 56 years (range:
29–72) received auto SCT between September 1997 and August
2006. Median serum creatinine and creatinine clearance (CrCl) at
auto SCT were 2.9 mg/dl (range 2.0 – 12.5) and 33 ml/min (range
8.7 – 63), respectively. Ten patients (22%) were dialysis-dependent.
Results: Median follow up in surviving patients was 34 months
(range 5–81). Complete (CR) and partial responses (PR) were seen
in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall
response rate of 75%. Two patients (4%) died within 100 days of
auto SCT. Grade 2–4 Non-hematological adverse events were
seen in 18 patients (39%) and included cardiac arrythmias, pulmo-
nary edema, hyperbilirubinemia. Median progression-free (PFS)
was 22.8 months and median overall survival OS has not yet been
reached. Kaplan-Meier estimates of 3-year PFS and OS were 36%
and 64%, respectively. Thirty patients (62.5%) are still alive after
a median follow up of 34 months, and 18 patients (39%) are alive
and progression-free. Significant improvement in renal function, de-
fined as an increase in GFR by 25% above baseline, was seen in 17
patients (37%). None of the 10 dialysis-dependent patients became
dialysis independent. A pre-transplant creatinine level of $3mg/dlwas associated with a significantly shorter overall survival (p 5
0.05, HR 2.8).
Conclusions: Auto SCT was safe and feasible in selected patients
with MM and renal failure, and was associated with a significant im-
provement in renal function in approximately one-third of the trans-
planted patients.103
CYTOREDUCTIVE REGIMEN CONTAINING RANIMUSTINE (MCNU), CAR-
BOPLATIN, ETOPOSIDE AND CYCLOPHOSPHAMIDE (MCEC) BEFORE AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(PBSCT) FOR RELAPSED OR REFRACTORY LYMPHOMA
Asakura, Y., Tanosaki, R., Kim, S.-W., Azuma, T., Kurosawa, S.,
Yakushijin, K., Maruyama, D., Mori, S.-i., Fukuda, T., Watanabe, T.,
Kobayashi, Y., Tobinai, K., Takaue, Y. National Cancer Center Hospital,
Chuo-ku, Tokyo, Japan
MCNU, a derivative of nitrosourea that was developed in Japan,
shows good penetration into CSF and might be expected to decrease
CNS relapse of lymphoid malignancies when used before transplan-
tation. However, its feasibility and efficacy have not been extensively
analyzed in adult patients with lymphoma. We retrospectively eval-
uated anMCEC regimen which consisted ofMCNU (200mg/m2 on
days -8 and -3), carboplatin (300 mg/m2 on days -7 through -4), eto-
poside (500 mg/m2 on days -6 through -4) and cyclophosphamide
(50 mg/kg on days -3 and -2) in 68 patients with lymphoma (median
age, 48 yr: range, 20–65 yr) who underwent autologous PBSCT at
our institution between Jan. 1999 and Feb. 2008. The diagnosis in-
cludedDLBCL (N5 33), FL (14), including 6 transformants, T-cell
lymphoma (12), and HL (9). The median time from diagnosis to
PBSCTwas 20 months (4–198 mo), and the median number of prior
chemotherapy regimens was 3 (2–7). 97% had ECOG PS\ 2, 41%
had prior XRT, 4% had bulky disease, 62% had stage III-IV disease,
28% had IPI at relapse of H/H-I. The disease status at PBSCT was
1st CR/PR in 15%, $ 2nd CR/PR in 72%, and NC/PD in 13%.
Grade (G) 4 non-hematological toxicities (CTCAE ver. 3.0) in-
cluded elevated transaminase (1), hyponatremia (1) and hypokalemia
(1). GI and CNS toxicities consisted of G3 mucositis (10), G3 diar-
rhea (27) and G2 seizure (1). There were no G4 cardiac, pulmonary
or renal toxicities except for one who died of treatment-related
MOF. The cumulative incidence of relapse at 2 yrs was 49 %. Of
33 relapses, 2 occurred newly in the CNS without any previous his-
tory.With a median follow-up of 24 months (3–80) after PBSCT for
surviving patients, the 2-yr OS and PFS were 68% (95% CI 55–
81%) and 50% (95% CI 38–63%), respectively. In univariate analy-
ses, T-cell phenotype (p\ 0.01), bulky disease (p\ 0.01), disease
status other than CR/PR (p\ 0.01), stage III-IV (P 5 0.03), IPI
(H/H-I, p \ 0.01) and treatment without rituximab (p \ 0.01)
were unfavorably associated with OS. Multivariate analysis con-
firmed that T-cell phenotype (HR 1.85; 95% CI 0.85–2.86, p \
0.01), bulky disease (HR 3.02; 95% CI 1.26–4.79, p\0.01), disease
status (HR 1.95; 95% CI 0.89–3.01, p\ 0.01), IPI (HR 2.66; 95%
CI 1.19–4.14, p \ 0.01) and treatment without rituximab (HR
4.12; 95% CI 1.14–7.10, p \ 0.01) were unfavorably associated
with OS. The results suggested that autologous PBSCT with the
MCEC regimen is a feasible and effective treatment option for re-
lapsed/refractory lymphoma.104
TIMING OF HIGH DOSE MELPHALAN (HDM) AND OUTCOMES FOR AU-
TOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH
MULTIPLE MYELOMA (MM)
Mahindra, A.1, Bolwell, B.1, Rybicki, L.2, Sobecks, R.1, Pohlman, B.1,
Andresen, S.1, Earl, M.1, Dean, R.1, Copelan, E.1, Kalaycio, M.1 1Cleve-
land Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
HDM is the most widely used preparative regimen for ASCT in
MM. The timing of HDM prior to transplantation has varied be-
tween studies. HDM is given on day –2 (2 days prior to stem cell
infusion) in some and on day –1 in others. At our institution,
HDM was initially given on day -2. Considering Melphalan un-
dergoes rapid hydrolysis in plasma with a short half-life in the or-
der of 60–90 minutes, administration on day -1 seemed feasible and
42 Poster Session-Iour protocol was modified. We report a single-institution experi-
ence using HDM as a preparative regimen in 40 consecutive pts
with MM receiving melphalan on day 22 or day 21. Between
July 2003 and May 2008, 40 pts with MM underwent HDC with
ASCT using HDM either on day –2 (n 5 13) or day –1(n 5 27)
in sequential cohorts. The two groups were similar with respect
to age, gender, ISS stage, number of prior chemotherapy regimens,
prior radiation therapy, FEV1 and DLCOc pre transplantation.
The median CD341 dose (106 /kg) was 5.82 (range, 2.78–
13.68) in the group treated with HDM on day 22 and 3.36 (range,
2.06–10.71) in the group treated with HDM on day 21 (p\0.001).
Pts treated with HDM on day -2 recovered granulocytes at a me-
dian of day 11 (range, 10–12) whereas pts treated on day -1 recov-
ered by day 13 (range, 11–17) post-transplant (p\0.001); this
difference remained significant after adjusting for CD341 dose
(p\0.001). Pts achieved platelet counts more than 20,000/mL at
a median of 12 days (range, 10–27) post-transplant in the group re-
ceiving HDM on day 22 and by 13 days (range, 8–19) in the group
treated on day –1 (p 5 0.74). Pts receiving HDM on day -1 had
worse mucositis as measured by the oral mucositis assessment scale
(p 5 0.027). In the group receiving HDM on day 22, 12 pts (92%)
are alive with a median follow up of 7 mths (range, 3.8–18.7). In the
group receiving HDM on day -1, 24 pts (89%) are alive with a me-
dian follow up of 27.8 mths (range, 1.2–55.4). There was no signif-
icant difference observed in the median relapse-free survival (p 5
0.56) or overall survival (p 5 0.48) between the two groups. Mel-
phalan has a short half-life on the order of 60–90 minutes and
hence administration on day 21 seems feasible. However, our
data indicates that the time to granulocyte engraftment is shorter
in pts receiving HDM on day –2, time to platelet engraftment is
similar and severity of mucositis is lower. These data suggest that
administration of HDM on day 22 may improve hematopoietic re-
covery and decrease mucositis.105
A MD3100: SUCCESSFUL MOBILIZATION IN PATIENTS WHO FAIL STAN-
DARDMOBILIZATIONWITH GOOD TRANSPLANT OUTCOME AND NO SIG-
NIFICANT TOXICITY
Kannarkat, G.T., Beveridge, R., Eichna, D., Scherer, D., Sampl, K.,
Salam, A., Sese, G.B., Lucy Nam, M.H., Mintz, K., Soubra, M.,
Orloff, G. INOVA Fairfax Hospital, Fairfax, VA
AMD3100 reversibly inhibits the binding of SDF-1 to CXCR4,
which normally regulates the migration of hematopoeitic stem cells
(HSC) from the bone marrow. Used in conjunction with G-CSF,
rapid mobilization of CD341HSC into the peripheral bloodstream
can be achieved. In addition to the standard mobilization protocol
with G-CSF, AMD3100 is administered through a compassion-
based protocol at 240 mg/kg in the evening before the first day of phe-
resis and every evening preceding subsequent days of pheresis. At our
institution, we report use of the drug when patients have failed to col-
lect 3.0 million CD341 cells after mobilization with G-CSF alone.
The ten patients (male n 5 5, median age 61 years [range 36–72])
on the study had diagnoses of non-Hodgkins lymphoma (n 5 7)
andHodgkin’s disease (n5 3).Median time from last dose of chemo-
therapy was 2 months [range 5 1–4] and 40 days [range 5 26–118]
between phereses. Before AMD31001 administration, the maxi-
mum total CD341 cell count collected per kg per day was 1.80 ver-
sus 5.80 after treatment [range 0.60–5.80]. Nine out of ten patients
successfully mobilized and proceeded to HSC transplant after use
of AMD3100. Patients who successfully mobilized cells after treat-
ment (median 5 2 days [range 5 1–4]) collected in total a median
of 4.80 million CD341 cells/kg [range 5 2.8–5.8]. For transplant,
a median of 3.30 million CD341 cells/kg [range 2.6–5.8] were in-
fused. Patients achieved ANC and platelet engraftment at a median
of 10 days [range 10–15] and 15 days [range 7–22], respectively.
On average, 2.8 units of red blood cells [range 5 0–6] and 6.2 units
of platelets [range 5 1–18] were required. There was no transplant
related mortality but one patient died at 28 days post transplant
from a myocardial infarction and another patient at 128 days post
transplant from cardiac arrest. No other serious adverse events
were reported. Our institution’s experience with AMD3100 demon-
strates success in mobilizing more CD341 cells in patients who fail
standard protocol, with good transplant outcome and without signif-
icant toxicity.106
SPONTANEOUS AUTOLOGOUS ACUTE GRAFT-VERSUS-HOST DISEASE
(GVHD) IN MULTIPLE MYELOMA (MM) AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) RECIPIENTS: A SURPRISINGLY HIGH INCIDENCE
Lazarus, H.M.1, Subbiah, S.1, Wakeling, A.1, Cooper, B.W.1,
Ataergin, S.A.1, Laughlin, M.J.1, Kindwall-Keller, T.1, Creger, R.J.1,
Barr, P.1, Gerson, S.L.1, Cooke, K.R.2 1University Hospitals Case Medical
Center, Cleveland, OH; 2Rainbow Babies and Childrens Hospital, Cleve-
land, OH
Five MM patients (pts) age 38–67 yr spontaneously developed au-
tologous acute GVHD limited to the GI tract (N 5 3) or GI tract/
liver (N 5 2) but clinically sparing the skin in all. Onset was docu-
mented via GI tract biopsy in all pts 7–27 days after ASCT. Peak se-
rum bilirubins were 5.5 and 4.5 mg/dL. All pts responded promptly
to prednisone (Pred) 1 or 2 mg/kg/d, or budesonide (Bud) oral ‘‘non-
absorbable’’ corticosteroid, or combination therapy.
Patient and clinical characteristics
Age / Initial Prior CD341 Onset Sites/ GVHD
Gender Stage Therapies x 106/kg aGVHDStage GVHD Therapy55yr/M IIIB k Bort/Dex; Cy 16.4 T17 GI 3 Pred 1/ Bud
62yr/F IIIA IgG k Thal/Dex;
Bort/Dex;
Mel/Pred8.1 T127 GI 4 Bud53yr/F IIIB IgG k Thal/Dex 5.2 T112 GI 3/liver 2 Pred 2
38yr/F IIA IgG k Thal/Dex/Bort 5.3 T19 GI 3/liver 2 Pred 2
67yr/F IIIA IgA l Rev/Dex 15.7 T116 GI 3 Pred 1For initial MM treatment all pts previously received Pred or dexa-
methasone (Dex) plus thalidomide (Thal), lenalidomide (Rev), or
bortezomib (Bort) therapy; all were given cyclophosphamide (Cy)
plus G-CSF for peripheral stem cell (PSC) mobilization followed
by ASCT using amifostine 740 mg/m2 (day T-2 and T-1) and mel-
phalan (Mel) 200 mg/m2 (day T-1). During this same 2006–2008
time period, we performed a total of N5 46 autologous PSC trans-
plants in MM patients age 38–71 yr using the same mobilization and
ASCT regimen; median (range) CD34 cell dose infused was 8.8 (3.5–
23.1) x 106/kg. Exposure to immunomodulatory agents may affect
blood T-regulatory cells (T-regs), cells that protect the host from au-
toimmune disease by suppressing self-reactive cells.The leukapheresis
products collected after PSC mobilization from such patients
may contain low concentrations of T-reg cells. Further, Mel-
containing regimens are associated with a higher incidence of
GVHD in the allogeneic setting (A Shimoni et al. Leuk 21:
2109, 2007). Although rare, autologous GVHD is potentially
a serious complication of ASCT. Despite absence of rash, this
condition should be considered in the differential diagnosis of
MM pts with otherwise unexplained GI symptoms or hepatic
dysfunction in the post-ASCT period. We hypothesize that
the combination of exposure to immunomodulatory agents be-
fore PSC collection and use of Mel in ASCT predispose select
pts to spontaneous autologous acute GVHD.107
FEASIBILITY OF CD34-POSITIVE STEM CELL MOBILIZATION BY ADMIN-
ISTRATION OF AMD3100 SIX HOURS PRIOR TO LEUKAPHERESIS
Chari, A.1, Vendivil, M.1, Clark-Garvey, S.1, Schwartz, J.2, Slotky, R.2,
Diuguid, D.1, Savage, D.1 1NYPH - Columbia University Medical Cen-
ter, New York, NY; 2NYPH - Columbia University Medical Center, New
York, NY
AMD3100, an inhibitor of the SDF-1 chemokine interaction
with the CXCR4 receptor, has allowed successful mobilization of
CD34 stem cells in patients with hematologic malignancies for
whom traditional GCSF based mobilization regimens have failed.
As part of a Compassionate Use Protocol (CUP), we have been
able to collect adequate stem cells in seven such patients. Based
on pharmacokinetic and pharmacodynamic data, the recommended
time of the subcutaneous administration of 240 mcg/kg of
AMD3100 is 10–11 hours before the start of apheresis (in addition
to standard GCSF administration timing). After treating three pa-
tients on this schedule, we found this timing to be impractical for
